Alnylam Pharmaceuticals Price Target, Predictions & Analyst Ratings

+0.75 (+0.45 %)
(As of 06/14/2021 02:33 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume12,152 shs
Average Volume621,015 shs
Market Capitalization$19.49 billion
P/E RatioN/A
Dividend YieldN/A

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
15 Wall Street analysts have issued ratings and price targets for Alnylam Pharmaceuticals in the last 12 months. Their average twelve-month price target is $172.07, predicting that the stock has a possible upside of 3.80%. The high price target for ALNY is $235.00 and the low price target for ALNY is $91.00. There are currently 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
TypeToday30 Days Ago90 Days Ago180 Days Ago
ALNY Consensus Rating: BuyBuyHoldBuy
ALNY Consensus Rating Score: 2.532.502.422.60
ALNY Analyst Ratings: 0 Sell Rating(s)
7 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
6 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
ALNY Consensus Price Target: $172.07$168.73$163.42$153.00
ALNY Price Target Upside: 3.80% upside12.02% upside9.46% upside14.58% upside

Alnylam Pharmaceuticals (NASDAQ:ALNY) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2021Morgan StanleyLower Price TargetOverweight$206.00 ➝ $205.00Low
4/20/2021Needham & Company LLCReiterated RatingBuyLow
3/1/2021GuggenheimReiterated RatingBuy ➝ Neutral$162.00Low
2/14/2021Royal Bank of CanadaReiterated RatingHoldLow
2/12/2021CitigroupDowngradeBuy ➝ Neutral$170.00 ➝ $175.00Low
2/12/2021BarclaysBoost Price TargetOverweight$162.00 ➝ $196.00Low
2/12/2021HC WainwrightBoost Price TargetBuy$225.00 ➝ $235.00Low
1/25/2021BMO Capital MarketsDowngradeOutperform ➝ Market Perform$185.00 ➝ $185.00High
1/13/2021CowenBoost Price TargetIn-Line ➝ Outperform$154.00 ➝ $197.00High
12/17/2020Piper SandlerBoost Price TargetOverweight$169.00 ➝ $181.00Low
11/24/2020SVB LeerinkBoost Price TargetMarket Perform$90.00 ➝ $91.00Low
10/15/2020Bank of AmericaLower Price TargetBuy$160.00 ➝ $157.00Low
10/12/2020Chardan CapitalReiterated RatingBuyLow
9/30/2020OppenheimerReiterated RatingHold$156.00Medium
9/30/2020Berenberg BankInitiated CoverageHold$145.00Medium
5/28/2020UBS GroupBoost Price TargetNeutral$111.00 ➝ $122.00Low
5/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$133.00 ➝ $137.00High
4/24/2020Evercore ISIInitiated CoverageBuy$160.00Low
4/14/2020Cantor FitzgeraldBoost Price Target$195.00 ➝ $202.00Low
4/14/2020Nomura SecuritiesLower Price TargetReduce$75.00 ➝ $74.00Medium
12/17/2019Piper Jaffray CompaniesBoost Price TargetOverweight$145.00 ➝ $155.00Medium
9/3/2019Stifel NicolausSet Price TargetBuy$116.00Low
5/23/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$80.00Medium
8/28/2018JMP SecuritiesSet Price TargetBuy$198.00Medium
8/13/2018B. RileyBoost Price TargetBuy ➝ Buy$210.00 ➝ $230.00High
8/6/2018Jefferies Financial GroupReiterated RatingBuy$149.00Low
(Data available from 6/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.